Crohn's Disease News and Research

Latest Crohn's Disease News and Research

La Jolla Institute scientist Hilde Cheroutre earns the 2009 NIH Director's Pioneer Award

A scientist at the La Jolla Institute for Allergy & Immunology has received one of the National Institutes of Health (NIH)'s top awards -- the 2009 NIH Director's Pioneer Award. The prestigious prize carries with it funding for total costs of up to $4.7 million over five years, and is designed to support the work of exceptionally creative scientists, whose novel proposals offer the potential to make extraordinary contributions to human health.

24 Sep 2009

Collaborative clinical care network at Cincinnati Children's Hospital Medical Center

Fostering innovation to speed the improvement of health care is the goal of an $8.3 million grant to researchers at Cincinnati Children's Hospital Medical Center.

24 Sep 2009

Comprehensive and practical overview of psoriasis

Treatments for psoriasis often present a therapeutic challenge to physicians because, besides affecting the skin, psoriasis may be associated with various comorbidities (for instance, depression, psoriatic arthritis, Crohn's disease and, in severe psoriasis, metabolic syndrome and cardiovascular diseases).

22 Sep 2009

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo’s oral, proprietary therapeutic for chronic autoimmune uveitis.

21 Sep 2009

Conference to focus on the impact of healthcare proposals on diagnostic testing

Enzo Biochem, Inc. (NYSE:ENZ) announced today that Kevin Krenitsky, MD, President of Enzo Clinical Labs, will present at the 27th Annual Lab Institute ’09, sponsored by Washington G2 Reports, on September 23, 2009 in Arlington, Virginia.

19 Sep 2009

Enzo expands its capability to perform simultaneous live-cell imaging of nuclear components

Enzo Life Sciences, a division of Enzo Biochem, Inc. (NYSE:ENZ), has added a novel new system to its CELLestial™ line of live cell analysis products, providing expanded capability to simultaneously image both the nucleus and the nucleolus in living cells, the Company announced today. Called the Total Nuclear-ID™ Green/Red Nucleolar/Nuclear Detection Kit, the new addition has been specifically optimized for demanding live cell microscopy applications.

17 Sep 2009

Mayo Clinic Health Letter discusses kidney stone treatment options

Ordinary, loud snoring doesn't seem to be harmful, according to the September issue of Mayo Clinic Health Letter. But snorers still may want to seek treatment to stop snoring, reduce embarrassment and improve sleep for themselves and their bed partner.

17 Sep 2009

Legislation grants improve research and employment initiatives in Indiana University medical campus

Indiana University School of Medicine scientists have received more than $12 million in grants funded by the federal economic stimulus legislation, funding that has bolstered both research initiatives and research employment on the medical center campus.

16 Sep 2009

Therapeutic principles of monoclonal antibodies

Professor Joachim R. Kalden, Member of the Department for Molecular Immunology, Nikolaus-Fiebiger-Zentrum, University Medical School Erlangen-Nuremberg, presents therapeutic principles based on monoclonal antibodies.

10 Sep 2009

Positive impact on medication adherence through Aetna's care management program

Aetna announced today results of an analysis from the first half of 2009, demonstrating an average medication adherence of over 95 percent for its members taking Specialty medications. Disease states evaluated in Aetna’s analysis include: multiple sclerosis, rheumatoid arthritis, HIV, Crohn's disease, Pulmonary Arterial Hypertension (PAH), psoriasis, Hepatitis C and asthma.

4 Sep 2009

T cells influence aggressive immune cells by regulating the chemical environment between cells

University of Michigan scientists say they have uncovered a fundamentally new mechanism that holds in check aggressive immune cells that can attack the body's own cells. The findings open a new avenue of research for future therapies for conditions ranging from autoimmune diseases to organ transplants to cancer.

2 Sep 2009

Fernando Pisani and 24 hockey players helped raise funds and awareness about Crohn's disease and ulcerative colitis

The spirit of giving back was as strong as ever this weekend at the first ever Score for Colitis & Crohn's event, which raised $20,000 for four gastrointestinal and digestive disease patient organizations from across the country. The Score for Colitis & Crohn's initiative, which took place at the West Edmonton Mall's Ice Palace on Saturday, August 29th, featured Fernando Pisani of the Edmonton Oilers and 24 aspiring young hockey enthusiasts who were all on hand to help raise funds and awareness about Crohn's disease and ulcerative colitis, the latter of which Pisani was diagnosed with in 2007.

31 Aug 2009

WERF to assess the hidden cost of endometriosis to society and women with the disease

The World Endometriosis Research Foundation (WERF) has raised sufficient funds to commence the first ever prospective study to assess the hidden cost of endometriosis to society and to women with the disease.

28 Aug 2009

Anti-glycan antibody positivity observed in celiac disease

Anti-microbial antibody formation has been reported in celiac disease. Relatively high positivity rates were observed for the conventional antibodies, for example, ASCA, anti-OmpW, and anti-I2, and they were known to decrease after a successful gluten free-diet. The importance of newly discovered inflammatory bowel disease-associated antibodies (including anti-glycan antibodies and anti-OMP) in celiac disease is not sure.

26 Aug 2009

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

26 Aug 2009

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome.

24 Aug 2009

SQI Diagnostics continues discussions with the FDA to market it's SQiDworks Diagnostics Platform in the US

SQI Diagnostics Inc. (TSX-V: SQD), a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced its financial and operational results for the third quarter ended June 30, 2009.

24 Aug 2009

4SC starts phase 2 trial in hepatocellular carcinoma with 4SC-201 (resminostat)

4SC AG, the German drug discovery and development company, today announced the dosing of the first patient in its Phase II trial with 4SC-201 (resminostat), a pan-histone deacetylase (HDAC) inhibitor, as a new potential treatment option for patients with advanced hepatocellular carcinoma (HCC), the most frequent form of liver cancer.

18 Aug 2009

Experimental treatment for multiple sclerosis reverses disorder in mice

A new experimental treatment for multiple sclerosis (MS) completely reverses the devastating autoimmune disorder in mice, and might work exactly the same way in humans, say researchers at the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal.

11 Aug 2009

Predictors of disease behavior change in patients with Crohn's disease

Using the Vienna classification system, it has been shown in clinic-based cohorts that there can be a significant change in disease behavior over time, whereas disease location remains relatively stable. Clinical and environmental factors as well as medical therapy might be relevant in predicting disease behavior change in patients with CD.

11 Aug 2009

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

La Jolla Institute scientist Hilde Cheroutre earns the 2009 NIH Director's Pioneer Award

Collaborative clinical care network at Cincinnati Children's Hospital Medical Center

Comprehensive and practical overview of psoriasis

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Conference to focus on the impact of healthcare proposals on diagnostic testing

Enzo expands its capability to perform simultaneous live-cell imaging of nuclear components

Mayo Clinic Health Letter discusses kidney stone treatment options

Legislation grants improve research and employment initiatives in Indiana University medical campus

Therapeutic principles of monoclonal antibodies

Positive impact on medication adherence through Aetna's care management program

T cells influence aggressive immune cells by regulating the chemical environment between cells

Fernando Pisani and 24 hockey players helped raise funds and awareness about Crohn's disease and ulcerative colitis

WERF to assess the hidden cost of endometriosis to society and women with the disease

Anti-glycan antibody positivity observed in celiac disease

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

SQI Diagnostics continues discussions with the FDA to market it's SQiDworks Diagnostics Platform in the US

4SC starts phase 2 trial in hepatocellular carcinoma with 4SC-201 (resminostat)

Experimental treatment for multiple sclerosis reverses disorder in mice

Predictors of disease behavior change in patients with Crohn's disease

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in